Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(γ-methyl ε-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties.
1. An oxygen carrier composition, comprising:
a plurality of polymers;
an oxygen-binding compound containing at least one of a heme group or myoglobin subunit; and
at least one allosteric effector comprising a molecule that modifies oxygen binding through at least one of hydrogen ions, carbon dioxide, or 2,3-bisphosphoglycerate.
2. A composition, comprising:
an oxygen carrier, wherein the oxygen carrier is a polymersome comprising:
a plurality of polymers; and
an oxygen-binding compound containing at least one of a heme group or myoglobin subunit,
wherein the polymersome has an aqueous interior, and wherein the oxygen-binding compound is within the polymersome; and
an allosteric effector compartmentalized within the aqueous interior of the polymersome, wherein the allosteric effector modifies oxygen binding through at least one of hydrogen ions, carbon dioxide, or 2,3-bisphosphoglycerate.
3. A composition, comprising:
an oxygen carrier, wherein the oxygen carrier comprises:
a polymersome comprising a plurality of polymers; and
an oxygen-binding compound containing at least one of a heme group or myoglobin subunit,
wherein the polymersome has a hydrophobic membrane, and wherein the oxygen-binding compound is within the polymersome; and
a pharmaceutically active agent compartmentalized within the hydrophobic membrane of the polymersome.
4. A composition, comprising:
an oxygen carrier, wherein the oxygen carrier comprises:
a polymersome comprising a plurality of polymers; and
an oxygen-binding compound containing at least one of a heme group or myoglobin subunit,
wherein the polymersome has a hydrophobic membrane, and wherein the oxygen-binding compound is within the polymersome; and
an allosteric effector compartmentalized within the hydrophobic membrane of the polymersome, wherein the allosteric effector modifies oxygen binding through at least one of hydrogen ions, carbon dioxide, or 2,3-bisphosphoglycerate.
5. The composition of claim 4 , wherein the allosteric effector is a naturally occurring molecule, a recombinant molecule, a synthetic molecule, or a polymer.
6. An oxygen carrier composition, comprising:
a polymersome comprising a plurality of polymers;and
an oxygen-binding compound containing at least one of a heme group or myoglobin subunit,
wherein the polymersome has a hydrophilic surface, and wherein the oxygen-binding compound is covalently linked to the hydrophilic surface.
7. A composition, comprising:
an oxygen carrier, wherein the oxygen carrier is comprises:
a polymersome comprising a plurality of polymers; and
an oxygen-binding compound containing at least one of a heme group or myoglobin subunit,
wherein the polymersome has a hydrophilic surface; and
a pharmaceutically active agent covalently linked to the hydrophilic surface of the polymersome.
8. A composition, comprising:
an oxygen carrier, wherein the oxygen carrier comprises:
a polymersome comprising a plurality of polymers; and
an oxygen-binding compound containing at least one of a heme group or myoglobin subunit,
wherein the polymersome has a hydrophilic surface; and
an allosteric effector covalently linked to the hydrophilic surface of the polymersome.
9. The composition of claim 8 , wherein the allosteric effector is a naturally occurring molecule, a recombinant molecule, a synthetic molecule or a polymer.
10. The composition of claim 8 , wherein the allosteric effector modifies oxygen-binding through hydrogen ions, carbon dioxide, or 2,3-bisphosphoglycerate.